

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT AGENCY AND DISTRIBUTION AGREEMENT

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 23 March 2023 (after trading hours), Genezone International Health Management Limited (“**Genezone**”), an indirect non-wholly owned subsidiary of the Company, and Guangdong Unity Biotechnology Co., Ltd* (“**Unity**”, together with Genezone, the “**Parties**”), entered into an agency and distribution agreement (the “**Agreement**”), pursuant to which the Parties have agreed that, during the period from 23 March 2023 to 23 March 2032 (both days inclusive, and subject to a conditional extension of 10 years), Genezone shall become the exclusive authorised agent of Unity to distribute the adiponectin products as specified in the Agreement in Hong Kong, which includes an adiponectin test kit for the in vitro quantitative detection of adiponectin concentrations in human serum samples to assess the risk of type II diabetes and coronary heart disease.

THE AGREEMENT

The principal terms of the Agreement are set out below:

| | |
|-----------------|---|
| Date: | 23 March 2023 |
| Parties: | (I) Genezone; and (II) Unity |
| Term: | The period from 23 March 2023 to 23 March 2032 (both days inclusive, and subject to a conditional extension of 10 years) |
| Subject matter: | Pursuant to the Agreement, Genezone shall become the exclusive authorised agent of Unity to distribute the adiponectin products as specified in the Agreement in Hong Kong, which includes an adiponectin test kit for the in vitro quantitative detection of adiponectin concentrations in human serum samples to assess the risk of type II diabetes and coronary heart disease |

REASONS FOR AND BENEFITS OF ENTERING INTO THE AGREEMENT

Unity is a company established in the People's Republic of China and is a national high-tech enterprise that has close cooperation with the State Key Laboratory of Pharmaceutical Biotechnology at the University of Hong Kong. The Board believes that the entering into of the Agreement with Unity will be beneficial to the development of the Group's sales and distribution of health-related and pharmaceutical products segment and will maximise returns for the Company and the Shareholders.

DEFINITION AND GLOSSORY OF TECHNICAL TERM

“Adiponectin” an insulin-sensitizing hormone whose concentration in human serum can be used for early screening and diagnosis of type II diabetes and coronary heart disease

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 23 March 2023

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of the Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.

** for identification purpose only*